- Home
- WIW vs REPL Comparison
WIW vs REPL Comparison
Compare WIW & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- REPL
- Stock Information
- Founded
- WIW 2004
- REPL 2015
- Country
- WIW United States
- REPL United States
- Employees
- WIW N/A
- REPL N/A
- Industry
- WIW Finance Companies
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- WIW Finance
- REPL Health Care
- Exchange
- WIW Nasdaq
- REPL Nasdaq
- Market Cap
- WIW 540.9M
- REPL 547.0M
- IPO Year
- WIW N/A
- REPL 2018
- Fundamental
- Price
- WIW $8.91
- REPL $5.67
- Analyst Decision
- WIW
- REPL Buy
- Analyst Count
- WIW 0
- REPL 10
- Target Price
- WIW N/A
- REPL $8.25
- AVG Volume (30 Days)
- WIW 229.9K
- REPL 17.2M
- Earning Date
- WIW 01-01-0001
- REPL 08-07-2025
- Dividend Yield
- WIW 11.14%
- REPL N/A
- EPS Growth
- WIW N/A
- REPL N/A
- EPS
- WIW N/A
- REPL N/A
- Revenue
- WIW N/A
- REPL N/A
- Revenue This Year
- WIW N/A
- REPL N/A
- Revenue Next Year
- WIW N/A
- REPL $194.05
- P/E Ratio
- WIW N/A
- REPL N/A
- Revenue Growth
- WIW N/A
- REPL N/A
- 52 Week Low
- WIW $8.01
- REPL $2.68
- 52 Week High
- WIW $9.37
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- WIW 63.57
- REPL 45.73
- Support Level
- WIW $8.74
- REPL $5.08
- Resistance Level
- WIW $8.87
- REPL $5.84
- Average True Range (ATR)
- WIW 0.06
- REPL 0.46
- MACD
- WIW 0.01
- REPL 0.17
- Stochastic Oscillator
- WIW 98.82
- REPL 62.11
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.